TVTX — Travere Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1438533 ·
Last close
$55.89
Market Cap
$5.20B
52W High
$60.10
52W Low
$41.32
ADV30
1,738,867
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,199,000 | 100,433,000 | -36,915,000 | -37,102,000 | 555,188,000 | 78,362,000 | 456,460,000 |
| Dec 2025 | 129,689,000 | 127,136,000 | -32,428,000 | 2,729,000 | 605,191,000 | 93,035,000 | 490,363,000 |
| Sep 2025 | 164,859,000 | 163,274,000 | 24,931,000 | 25,706,000 | 538,581,000 | 110,930,000 | 465,017,000 |
| Jun 2025 | 114,449,000 | 112,928,000 | -12,650,000 | -12,755,000 | 555,309,000 | 75,154,000 | 522,562,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$39,612,000
Investing CF
$8,151,000
Financing CF
$-32,981,000
CapEx
$-68,551,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,509,815,000
Inventory
$6,356,000
Receivables
$87,302,000
ST Investments
$186,314,000
EBIT TTM
$-34,615,000
Pretax Income TTM
$-44,808,000
Interest Exp TTM
$10,193,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$536,195,008
EBITDA
$16,088,000
Free Cash Flow
$-51,166,000
Enterprise Value
$5,260,359,680
Total Cash
$264,676,000
Total Debt
$327,662,016
Shares Out
92,992,905
Trailing EPS
$-0.50
Book Value
$1.07
ROE
-69.4%
ROA
-6.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 490,728,000 | -62,824,000 | -25,546,000 | 605,191,000 | 490,363,000 | — | 37,784,000 |
| Dec 2024 | 233,175,000 | -321,389,000 | -321,545,000 | 594,125,000 | 535,048,000 | — | -237,475,000 |
| Dec 2023 | 145,238,000 | -376,744,000 | -111,399,000 | 788,913,000 | 588,103,000 | — | -280,021,000 |
| Dec 2022 | 109,460,000 | -319,813,000 | -278,482,000 | 672,585,000 | 629,734,000 | — | -186,291,000 |
TTM Snapshot
Revenues TTM
$196,285,000
NetIncome TTM
$-9,371,000
OpCashFlow TTM
$0
Assets (Latest)
$594,125,000
Forward EPS
$4.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | $5.68B | $68.01 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.73B | $40.01 | — |
| DYN | Dyne Therapeutics, Inc. | $4.70B | $25.18 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.76B | $287.54 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.82B | $96.51 | — |
News headlines (Yahoo Finance, 1h cache)
Stock Market Checklist Helps Uncover Winners In Hot Biotechs
2026-07-31 15:09 · Yahoo
Travere Therapeutics to Report Second Quarter 2026 Financial Results
2026-07-28 20:30 · Yahoo
This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026
2026-07-27 18:09 · Yahoo
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 21:00 · Yahoo
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
2026-06-13 20:45 · Yahoo
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
2026-06-08 17:38 · Yahoo
Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated Value
2026-06-03 17:38 · Yahoo
3 Stocks That May Be Priced Below Their Estimated Worth In June 2026
2026-06-03 11:38 · Yahoo
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside
2026-06-02 18:14 · Yahoo
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
2026-06-02 12:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.